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trial of targeted case finding for COPD versus
routine practice in primary care: protocol
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Robert A Stockley2, Sheila Greenfield1, Stanley Siebert4, Amanda Daley1 and David A Fitzmaurice1Abstract
Background: Many people with clinically significant chronic obstructive pulmonary disease (COPD) remain
undiagnosed worldwide. There are a number of small studies which have examined possible methods of case
finding through primary care, but no large RCTs that have adequately assessed the most cost-effective approach.
Methods/Design: In this study, using a cluster randomised controlled trial (RCT) in 56 general practices in the West
Midlands, we plan to investigate the effectiveness and cost-effectiveness of a Targeted approach to case finding
for COPD compared with routine practice. Using an individual patient RCT nested in the Targeted arm, we plan
also to compare the effectiveness and cost-effectiveness of Active case finding using a postal questionnaire (with
supplementary opportunistic questionnaires), and Opportunistic-only case finding during routine surgery consultations.
All ever-smoking patients aged 40-79 years, without a current diagnosis of COPD and registered with participating
practices will be eligible. Patients in the Targeted arm who report positive respiratory symptoms (chronic cough or
phlegm, wheeze or dyspnoea) using a brief questionnaire will be invited for further spirometric assessment to ascertain
whether they have COPD or not. Post-bronchodilator spirometry will be conducted to ATS standards using an Easy
One spirometer by trained research assistants.
The primary outcomes will be new cases of COPD and cost per new case identified, comparing targeted case finding
with routine care, and two types of targeted case finding (active versus opportunistic). A multilevel logistic regression
model will be used to model the probability of detecting a new case of COPD for each treatment arm, with clustering
of patients (by practice and household) accounted for using a multi-level structure.
A trial-based analysis will be undertaken using costs and outcomes collected during the trial. Secondary outcomes
include the feasibility, efficiency, long-term cost-effectiveness, patient and primary care staff views of each approach.
Discussion: This will be the largest RCT of its kind, and should inform how best to identify undiagnosed patients with
COPD in the UK and other similar healthcare systems. Sensitivity analyses will help local policy-makers decide which
sub-groups of the population to target first.
Trial registration: Current controlled trials ISRCTN14930255
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Chronic obstructive pulmonary disease (COPD) affects
5-10% of adults worldwide [1], is rising in prevalence [2],
and is a leading cause of death [3]. In the UK it accounts
for 1.4 million GP consultations, 1 million in-patient days
per year and costs the NHS over £800 million per year [4].
However, around 45-85% of cases [5-7], depending on
diagnostic criteria, remain undiagnosed, representing many
with potentially unmet need. There is much uncertainty
about how to approach early identification of patients [8,9],
although it has been recently demonstrated that there are
many missed opportunities to diagnose patients in primary
care where signs and symptoms have been overlooked [10].
The CMO's report, 2005 [11] and the Healthcare Com-
mission report [12] highlighted the burden of COPD, the
extent of under-diagnosis and variation in access to rele-
vant services. As a result a National Clinical Outcomes
Strategy has been published recommending case finding in
high risk patients [13], resulting in a British Lung Founda-
tion campaign [14] and drive to identify missing cases
[15,16]. Several NHS Trusts have started initiatives [17,18].
Despite the move towards early case-finding for
COPD, the most effective and cost-effective approach is
not known. There are no relevant published systematic
reviews, though many small pre-post studies have re-
ported on approaches to case finding. These report ei-
ther active [5,19,20] or opportunistic [21-24] approaches
(with yield 18-47%), but are limited because of a lack of
comparison groups, restricted number and range of par-
ticipants, incomplete follow up or different target popu-
lations. More recently a few trials have been published.
A small trial from a single practice reported a higher
prevalence of airflow obstruction with an opportunistic
compared to invitation based approach to case finding
[25]. The population however was highly deprived, with
many non-English speakers, and no economic analysis
was undertaken. A cluster RCT in 16 general practices
in the Netherlands which used an initial screening ques-
tionnaire to identify patients at risk found that a practice-
managed approach to calculating the score and inviting
patients for spirometry assessment was more effective
than a patient-led approach of applying for spirometry
assessment having calculated their own scores [26].
Additionally, we have also reported a pilot study in two
general practices which suggested that it may be more
cost-effective to undertake opportunistic screening; how-
ever the study was underpowered and the results require
proper testing in a full RCT [27]. The limitation of the
current evidence base and lack of adequate data from
RCTs contributed to the recent recommendation by the
UK National Screening Committee against screening for
COPD [28], and justifies a new adequately-powered trial.
Many studies have used spirometry alone to screen for
COPD. However this is not recommended [8] as it wouldidentify many without clinically important disease for
whom there is little evidence of effective interventions
[29,30]. National Institute for Clinical Excellence (NICE)
guidelines recommend opportunistic case finding in those
presenting with relevant symptoms and exposures (mainly
smoking) [31]. Our analysis of the Health Survey for Eng-
land (HSE), a large dataset representative of the English
population, shows that targeted case-finding among
smokers aged ≥40 with relevant symptoms would have
greater yield than targeting the general population [32].
Of the undiagnosed cases likely to be detected, more than
three quarters could benefit from evidence based treat-
ment (e.g. pulmonary rehab, inhaled therapies, vaccination
& smoking cessation interventions), and there is new evi-
dence that others may also benefit [33]. Modelling of
data from the Health Survey for England indicated that
active case-finding (with postal questionnaire plus op-
portunistic case-finding in primary care consultations)
would be more effective than opportunistic case-finding
alone, but this needs empirical testing [32].
Cases identified are expected to benefit from treatment
resulting in improved quality of life, increased survival, re-
duction in hospital admissions and less work-related ab-
sence. Published economic evaluations in COPD have
primarily considered interventions for the disease rather
than diagnosis, and others have concentrated on the costs
of COPD in burden of illness studies. No trial-based
economic evaluation has considered case-finding. NICE
guidelines included simple decision-tree based model-
ling to determine the cost-effectiveness of opportunistic
case finding among ever smokers over 35 years old with
chronic cough [31]. The model is simplistic, contains
many assumptions and requires better data on the natural
history of the disease. The proposed cost-effectiveness
component of this study will resolve this issue.
In this study, using a cluster RCT in general practices
across the West Midlands, we plan to investigate the effect-
iveness and cost-effectiveness of a Targeted approach to case
finding for COPD compared with routine practice. Using an
individual patient RCT nested in the targeted arm, we plan
also to compare the effectiveness and cost-effectiveness of
Active case finding using a postal questionnaire (with sup-
plementary opportunistic questionnaires), and Opportunis-
tic case finding at routine surgery consultations.
Methods
Aims and objectives
 To determine whether Targeted case finding is
more effective and cost-effective than routine
practice.
 To evaluate the relative effectiveness and
cost-effectiveness of two alternative methods of
targeted case finding: Active (postal questionnaire
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(flagging only).
Design
TargetCOPD is a pragmatic randomised controlled trial
of a case-finding intervention, delivered at organisational
level, with two elements (Figure 1):
1. Cluster randomised trial comparing Targeted case
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Patients will be identified as eligible if they are:
 registered at a participating practice
 aged between 40 and 79 years (inclusive) on the date
of the record search,
 identified as current or ex-smokers according to
their patient records
 have no prior diagnosis of COPD
Automated computer searches will be used for identi-
fying all eligible patients using READ codes (Additional
file 1: Appendix 1). Patients will be further assessed for
eligibility to take part in assessments by their GP and
those not considered suitable will not be invited for as-
sessment (e.g. if unable to give informed consent, suffer-
ing from a terminal illness or pregnant).
Intervention
All interventions will take place over one year. The schema
is given in Figure 1 with projected patient numbers. Fifty
six practices will initially be randomised to continue with
routine care or to a targeted approach to case finding.
Routine practice arm
In the routine practice arm of the cluster trial, practices
will continue with their usual care and new cases of
COPD will be identified according to usual practice.
NICE guidance recommends that patients over the age
of 35 years should be investigated for COPD with spir-
ometry if they present opportunistically with chronic
cough or phlegm [31].
Targeted case finding arm
Within the targeted arm of the cluster trial, participants
will be randomly allocated (by household) to receive either
the Opportunistic or the Active case finding intervention:
Stage 1: respiratory questionnaire
Opportunistic Patients in this arm will have their re-
cords flagged to prompt the consulting healthcare prac-
titioner or receptionist to provide them with a brief
screening questionnaire consisting of simple respiratory
questions supplemented with basic socio-demographic
and medical information (Additional file 1: Appendix 2).
The questionnaire is based on validated questions, where
available, and has been piloted. Patients who agree to take
part will leave the questionnaire with the receptionist.
Active In addition to having their records flagged to
allow opportunistic provision of the questionnaire, eli-
gible patients in the Active arm will also be sent a postal
questionnaire (with reply-paid envelope). If the question-
naire has not been received within four weeks afterposting, then a first reminder will be sent. After a fur-
ther four weeks, a second reminder will be sent. (It has
been shown that the response rate to respiratory ques-
tionnaires is maximized with two reminders) [34].
Once the questionnaire has been returned to the investi-
gators, the computer flag will be removed.
Stage 2: spirometry assessment
Any patient responding positively to the respiratory
symptom questions (chronic cough or phlegm for three
or more months of the year for two or more years,
wheeze in the last 12 months or dyspnoea of MRC grade
2 or more) will be invited to attend for spirometry to as-
certain whether they have COPD or not.
This will take place in a room at the patient’s GP prac-
tice or an alternative local venue. Post-bronchodilator
spirometry will be undertaken according to ATS/ERS
2005 guidelines [35] and carried out by research assis-
tants trained to high standards using a short modified
programme modelled on the ARTP Spirometry course
by the lung function unit at Queen Elizabeth Hospital
Birmingham. The research assistants will undertake fre-
quent refresher training and monitoring of quality
throughout the trial. FEV1, FVC, FEV6 will be measured
using the Easy One spirometer (ndd, Switzerland). Pa-
tients will be administered 400 micrograms salbutamol
through a spacer, and asked to rest for 20 minutes prior to
undergoing spirometry. Customised software (MMiller)
will be used to ensure real-time quality of each manoeuvre
and every trace over-read.
All spirometry results will be provided to their GP.
During the assessment visit, patients will also be asked
to complete a short questionnaire to ascertain their out
of pocket expenses for attendance (Additional file 1:
Appendix 3), health status (EQ-5D) [36], job type (using
CASCOT software) and the COPD Assessment Test. [37]
Patients’ height will be measured to the nearest cm using
a portable stadiometer (or estimated using arm-span if ne-
cessary), and weight (to the nearest 0.1 kg) will also be
measured using GP scales by trained researchers.
Allocation to trial arm
Cluster randomised trial comparing targeted case finding
with routine care
Recruited practices will be allocated into intervention
arms using block randomization. Ideally block size will
be at least eight practices [38,39], with an equal number
of practices allocated to intervention and control groups
by the end of each block.
A minimization algorithm will be used to allocate
practices to intervention groups to ensure balance across
the groups for the following covariates: deprivation, eth-
nicity, practice size, age and proportion of COPD pa-
tients on the Quality and Outcomes Framework (QOF)
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tices that have the same GPs across two sites, each with
a different patient list) will be stratified so that the allo-
cation to trial arm will be the same in order to avoid
contamination. The algorithm generates an ordered list
of the possible permutations of randomization within
each block – at the top of the list are the permutations
which minimize imbalance the best. Of those at the top
of the list (e.g. the top 10%), one will be chosen at ran-
dom to use.
Individually randomised RCT comparing active with
opportunistic case finding
Within each practice randomised to the Targeted arm,
each household will be further randomised to either ac-
tive or opportunistic case finding. Thus in the event of
multiple patients from the same household, they will
therefore be allocated the same intervention group in
order to avoid contamination. Allocation will be under-
taken automatically by the research database as each
practice list is uploaded.
Outcomes
Primary outcomes
The primary outcomes are the percentage of the eligible
population diagnosed as new COPD cases within the
first year, and cost per additional case identified in each
arm, comparing:
1. Targeted case finding and routine practice
2. Active and opportunistic case finding
Secondary outcomes
1. Feasibility (process measures such as uptake and
resource needs).
2. Efficiency (number needed to target to identify one
person likely to benefit).
Diagnosing COPD
For the cluster part of the trial, patients in the routine
arm may only be newly diagnosed with COPD during
usual care and will be identified from GP records using
the same method as that used to identify and exclude
patients with a prior diagnosis of COPD in the initial
search (Additional file 1: Appendix 1). The current NICE
guidance is that patients with appropriate chronic re-
spiratory symptoms must also meet spirometric criteria
(FEV1/FVC < 0.7) [31]. Thus, in order to compare with
routine care, our primary definition must be FEV1/FVC
< 0.7 in the presence of respiratory symptoms. However
this definition is controversial, and therefore, we propose
also to use the “Lower Limit of Normal” (LLN) defin-
ition using the recently established GLI 2012 equations[41]. This requires that the post-bronchodilator FEV1/
FVC ratio falls below the 5th percentile of the predicted
values for patients’ age, height, sex and ethnicity. All pa-
tients must also report chronic respiratory symptoms. In
sensitivity analyses we will explore other definitions such
as use of different cut-offs for the LLN.
Additional data collection
Data on the practices and patients will be collected at
several stages during the trial:
Practice level information
Information on the characteristics of each of the partici-
pating practices will be collected, to include list size,
number of eligible patients, number of existing COPD
patients, deprivation score, rural/urban status, ethnicity
profile, number of GPs, designated practice contacts and
age profile of the practice.
Information on all eligible patients
At baseline, practices will provide an anonymised dataset
on each of the eligible patients (in both routine practices
and targeted arms) to allow comparison between the
arms of the trial. To include: age, sex, ethnicity, smoking
status, co-morbidities, health service use and reasons for
exclusion.
At the end of the year, practices will also provide infor-
mation on the number of consultations for each eligible
patient, number of new cases of COPD identified out-
side or within the trial, whether patients have left the
practice or have died, and among a sample, the number
of flags remaining on the GP system to give an indica-
tion of the proportion of questionnaires distributed
opportunistically.
Statistical justification for sample size
As there are two primary outcomes, the significance
level for multiple testing is adjusted so that in total
(across both sample size calculations) there is a 5% sig-
nificance level. The individually randomised component
(outcome (b) below) comparing Active versus Opportun-
istic case finding requires far fewer patients for adequate
power and is therefore given 0.25% significance level.
The cluster component (a) is designated 4.75% signifi-
cance level.
(a) Targeted case finding versus Routine care cluster
randomized design
Based on the authors’ modelling work [32], the propor-
tion of new COPD cases detected in the Targeted group
(averaged across both Active and Opportunistic arms)
was assumed to be 3.15%. Based research by Simpson
et al. [42], the proportion of new COPD cases detected
in the Routine care group was assumed to be 0.75%. At
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an unadjusted sample size required of 545 per group, in
order to detect a difference of 2.4% between Targeted
and Routine care arms.
We expect ~40% of a practice population to be age
40-79 yrs with 57% of these being ever smokers without
a previous diagnosis of COPD [32]. Assuming therefore
a conservative 1000 eligible patients per practice of aver-
age list size 6000, and adjusting for clustering of patients
within practices, assuming a conservative ICC of 0.05
[43,44] the sample size required was 27,768 per arm,
equivalent to 28 practices per arm.
(b) Targeted arm: Active versus opportunistic case finding
The following estimates are based on assumptions
drawn from the authors’ previous modelling work [32].
We assume 50% allocated to the Active arm will re-
spond; of the remaining patients 91% will visit their GP
at least once in 12 months, 50% are offered the question-
naire and 90% of these will fill it out. In the Opportunistic
arm we assume 50% are offered the questionnaire and of
these 90% complete questionnaires (Figure 1). Of all re-
sponders to the questionnaire in both arms, we assume
48% are likely to report symptoms and be invited to spir-
ometry, of which 70% will attend and 17% of these will
have COPD. This leads to yield of 2.3% in the Opportunis-
tic and 4.0% in the Active arms. At a 0.25% significance
level, 3904 patients/arm are required to detect this differ-
ence with 90% power.
For the targeted case finding comparison, there will be
19,152 eligible in each arm, giving ample power for the
primary comparison (based on above assumptions 448
new cases from Opportunistic arm and 771 from Active
arm). This sample size provides additional power for sec-
ondary analyses and also allows more flexibility should the
assumptions be more optimistic than anticipated.
Statistics and data analyses
All statistical analyses will be undertaken in STATA ver-
sion 13.
Primary analyses
There are two primary comparisons:
Targeted case finding vs Routine care (cluster design)
Baseline characteristics of patients and uptake rate at
each stage will be described for each cluster, and com-
pared across clusters to check for balance across groups.
A multilevel logistic regression model will be used to
model the probability of detecting a new case of COPD
in the Targeted group compared with the Routine care
group. Clustering of patients (by practice and household)
will be accounted for using a multi-level structure. The
data will also be modelled using a log-link and resultsfrom the logit-link and log-link models will be compared.
OR and also RR and risk differences will be estimated
[45,46], as will the NNT (Number Needed to Target to
identify one additional COPD case). The analysis will also
adjust for variables used in the randomization (age, ethni-
city, deprivation) which might affect probability of having
COPD.
Within the targeted group, active case finding vs
opportunistic case finding (individual patient design)
Baseline characteristics of patients will be compared
for each arm (Active and Opportunistic) within each
practice to check for balance. Clustering of patients
within practices and households (if appropriate) will be
accounted for using a multilevel logistic regression
model. OR and also RR and risk differences will be
estimated [45,46], as will the NNT (Number Needed
to Target to identify one additional COPD case). Between-
practice heterogeneity in the effect of Active versus Op-
portunistic case finding will be examined, and if present,
the range and variability of effects will be appropriately
summarized.
Secondary analyses
In addition the following analyses are also of interest:
 Multilevel logistic regression will be used to
compare each of the two components of the
Targeted arm with Routine care
 Models will also be extended to estimate the effect
of practice-level covariates on rates of COPD
detection
 Interaction terms will also be included to assess
whether patient-level factors such as age, sex,
ethnicity, symptom profile and smoking history
modify (interact with) treatment effects.
 The impact of clustering at the household level will
be investigated in sensitivity analyses.
Economic analysis
The trial-based health economic analysis will consider
two questions:
How cost-effective is a) an Active approach to case-
finding and b) a simple Opportunistic approach compared
with routine detection of COPD (routine care), in terms
of cost per additional case detected?
A within-trial patient level analysis will be undertaken
to determine the total and mean costs of case finding for
each trial arm. An incremental cost-effectiveness analysis
from a health care perspective will determine the cost
per additional case detected, with a sensitivity analysis
taking into account patient out of pocket costs in addition
to health care costs. True cases of COPD detected by each
method will be determined within the trial. The cost of
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trial, and resource use data will be collected for each
method and will include staff time, equipment, diagnostic
testing and any consumables required. Data will be col-
lected from a representative sample of practices to ensure
generalisability. Unit costs (e.g. staff costs, equipment) will
be collected from published sources. In addition a patient
cost questionnaire will be administered to all who attend
for spirometry to determine their out of pocket (travel and
time) costs.
By using data from the trial which uses West Mid-
lands’ practices only, there may be limits to the general-
isability of the results of the trial. This will be explored
within the economic evaluation using extensive sensitiv-
ity analysis. Key parameters will be varied to determine
the impact of changes on results. Case finding in different
patient sub-groups will also be considered. Non-parametric
bootstrapping and probabilistic sensitivity analysis will be
undertaken to explore uncertainty in the confidence to be
placed on the results of the economic analysis and cost ef-
fectiveness acceptability curves presented.
Additional analyses
We also plan further related analyses not detailed here
including:
1. A model-based cost-effectiveness analysis to consider
longer-term effects of case-detection and subsequent
treatment (cost per quality-adjusted life year gained)
2. A qualitative study exploring patients views of
case-finding
3. A qualitative study exploring the views of healthcare
professionals
Patient advisory group
A patient advisory group (PAG) has been set up, chaired
by Mr Michael Darby. This group is funded to meet at
approximately quarterly intervals or according to need,
and will advise on a range of aspects of the design, con-
duct, analysis and dissemination of the study. The PAG
will discuss issues as requested by the CIs and the chair
will report their comments back to the investigators.
Data management
All data will be stored on a password-protected web-
enabled customized database designed and hosted by the
PC-CTRU. Paper-based information will be held in locked
filing cabinets in the study office.
Trial steering committee
We have established a Trial Steering Committee which
will meet annually to advise the research team.
Chair: Prof Debbie Jarvis, Imperial
Statistician: Prof Simon Gates, WarwickHealth economist: Dr Jane Wolstenholme, Oxford
Patient representative: Mr Michael Darby
Investigators: Dr Rachel Jordan, Prof David
Fitzmaurice, Prof Peymane Adab.
Data monitoring committee
This is not a trial of a medicinal product and therefore
does not require a data monitoring committee. However,
the TSC will undertake some of this role.
Interim analyses & stopping rules
There are no planned interim analyses or stopping rules
as the study must run for a full calendar year in each gen-
eral practice in order to allow the opportunistic interven-
tion to occur.
Regulatory issues
Ethics approval
The study has received ethical and research governance
approval through the IRAS process. Ref: 11/WM/0403.
Patient consent
Patients receiving the initial screening respiratory ques-
tionnaire will receive a letter of invitation, and patient
information leaflet (PIL) (Additional file 1: Appendix 4)
and will provide consent by returning their questionnaire
with the associated permissions and their contact details.
Patients attending spirometry assessment will discuss the
trial with the researcher and provide written consent to
participate (Additional file 1: Appendix 5). Permission
will also be sought to contact patients for future re-
search studies.
Indemnity
The University of Birmingham holds the relevant insur-
ance policy for this study.
Sponsor
The University of Birmingham will act as the main spon-
sor for this study.
Funding
National Institute for Health Research (NIHR) Programme
Grants for Applied Research Programme (Grant Reference
Number RP-PG-0109-10061).
Start date: July 2012
Proposed reporting date: July 2015
Publication plan
The main trial paper reporting the effectiveness and
trial-based cost-effectiveness analysis will be submitted
initially.
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This trial investigates the effectiveness and cost-
effectiveness of two alternative modes of systematic
case-finding for COPD compared with routine care.
Previously undiagnosed patients aged 40 years and over
with a positive smoking history will either receive a re-
spiratory questionnaire when they routinely visit their
surgery, or will also receive a questionnaire through the
post. Those with indicative respiratory symptoms will
be offered spirometry to diagnose COPD. There are
many strengths of this study including: it is the first of
this design based in a large sample of GP practices with
a comparator group; it is set in a range of GP practices
representative of urban UK; it has a pragmatic design
which should reflect real life; the spirometry will be the
best quality possible with highly trained staff and quality
control; there will be a full cost-effectiveness analysis
and also sensitivity analyses to reflect a range of scenar-
ios; the effects will be explored across the range of GPs
involved, allowing the cost-effectiveness in different
types of GPs to be assessed. This trial should inform
practice across the UK and elsewhere with similar
healthcare systems, and help to direct current effort to-
wards case-finding more efficiently.
However, a study of this size and complexity has many
challenges. We will be coordinating a large number of
practices, and as a screening trial, thousands of patients
and patient data. Accurately identifying appropriate pa-
tients from GP databases with their complex coding is a
known problem. It is not known how patients will re-
spond to questionnaires, and whether (or how often) it
is practical for GP staff to give out screening question-
naires during routine visits. These are some of the feasi-
bility outcomes we will be measuring. Coordinating and
arranging patient assessments with the dual issues of pa-
tient and GP capacity will also be a challenge, especially
in the short time-frame. And finally, it will be important
to discuss how this approach can be rolled out from a
trial setting into routine practice.Additional file
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